Andere talen Iovance Biotherapeutics, Inc.

Aandelen

IOVA

US4622601007

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,64 ^USD	+0,87%		+2,92%	+43,17%

29/03	Generaal (Ret.) Merrill A. McPeak, lid van de Raad van Bestuur van Iovance Biotherapeutics, Inc. Gaat met pensioen en stelt zich niet herkiesbaar	CI
14/03	IOVANCE BIOTHERAPEUTICS, INC. : Piper Sandler ontvangt een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting	24/04
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024	22/04
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	19/04
General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	29/03
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	25/03
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	22/03
Iovance Biotherapeutics to Present at Upcoming Conferences	04/03
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	04/03
Iovance Biotherapeutics Says FDA Lifts Partial Clinical Hold on Lung Cancer Study	04/03
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145	04/03
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer	04/03
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	04/03
Iovance Biotherapeutics to Present at Upcoming Conferences	01/03
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	29/02
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	29/02
Iovance Biotherapeutics: Q4 Earnings Snapshot	28/02
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Reports Q4 Revenue $482,000	28/02
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	28/02
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Iovance Biotherapeutics, Inc.

Aandelen

IOVA

US4622601007

Andere talen

Filters